Cumberland Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.6201
- Today's High:
- $1.675
- Open Price:
- $1.675
- 52W Low:
- $1.54
- 52W High:
- $2.91
- Prev. Close:
- $1.65
- Volume:
- 10018
Company Statistics
- Market Cap.:
- $23.84 million
- Book Value:
- 2.52
- Revenue TTM:
- $40.06 million
- Operating Margin TTM:
- -14.84%
- Gross Profit TTM:
- $32.89 million
- Profit Margin:
- -9.97%
- Return on Assets TTM:
- -3.99%
- Return on Equity TTM:
- -10.61%
Company Profile
Cumberland Pharmaceuticals Inc had its IPO on 2009-08-11 under the ticker symbol CPIX.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Cumberland Pharmaceuticals Inc has a staff strength of 85 employees.
Stock update
Shares of Cumberland Pharmaceuticals Inc opened at $1.68 at the start of the last trading session i.e. 2023-06-02.
The stocks traded within a range of $1.62 - $1.68, and closed at $1.65.
This is a -0.3% slip from the previous day's closing price.
A total volume of 10,018 shares were traded at the close of the day’s session.
In the last one week, shares of Cumberland Pharmaceuticals Inc have increased by +0.92%.
Cumberland Pharmaceuticals Inc's Key Ratios
Cumberland Pharmaceuticals Inc has a market cap of $23.84 million, indicating a price to book ratio of 0.7985 and a price to sales ratio of 0.7933.
In the last 12-months Cumberland Pharmaceuticals Inc’s revenue was $40.06 million with a gross profit of $32.89 million and an EBITDA of $-1014566. The EBITDA ratio measures Cumberland Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Cumberland Pharmaceuticals Inc’s operating margin was -14.84% while its return on assets stood at -3.99% with a return of equity of -10.61%.
In Q1, Cumberland Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 17.5%.
Cumberland Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.29 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cumberland Pharmaceuticals Inc’s profitability.
Cumberland Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0.712 and a EV to EBITDA ratio of -24.1162. Its price to sales ratio in the trailing 12-months stood at 0.7933.
Cumberland Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $89.47 million
- Total Liabilities
- $25.71 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $174453
- Dividend Payout Ratio
- 0%
Cumberland Pharmaceuticals Inc ended 2023 with $89.47 million in total assets and $0 in total liabilities. Its intangible assets were valued at $89.47 million while shareholder equity stood at $36.36 million.
Cumberland Pharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $25.71 million in other current liabilities, 47377168.00 in common stock, $-11016657.00 in retained earnings and $914000.00 in goodwill. Its cash balance stood at $16.39 million and cash and short-term investments were $16.39 million. The company’s total short-term debt was $158,369 while long-term debt stood at $16.07 million.
Cumberland Pharmaceuticals Inc’s total current assets stands at $43.81 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $14.53 million compared to accounts payable of $11.22 million and inventory worth $10.18 million.
In 2023, Cumberland Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $174453.
Comparatively, Cumberland Pharmaceuticals Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $1.65
- 52-Week High
- $2.91
- 52-Week Low
- $1.54
- Analyst Target Price
- $8.5
Cumberland Pharmaceuticals Inc stock is currently trading at $1.65 per share. It touched a 52-week high of $2.91 and a 52-week low of $2.91. Analysts tracking the stock have a 12-month average target price of $8.5.
Its 50-day moving average was $1.8 and 200-day moving average was $2.24 The short ratio stood at 0.94 indicating a short percent outstanding of 0%.
Around 4531% of the company’s stock are held by insiders while 1746% are held by institutions.
Frequently Asked Questions About Cumberland Pharmaceuticals Inc
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.